|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.01|
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia” or the “Company”) has appointed Dr. Sam Hanna as Chief Medical Officer of its cannabis dermatology division. Dr. Hanna is a well-recognized Canadian dermatologist with experience in numerous clinical studies for dermatology drugs across North America. The Company announced the appointment of Dr. Hanna on January 10, 2018, as Special Advisor to Belgravia’s wholly owned subsidiary, ICP Organics.
TORONTO, March 12, 2018-- BELGRAVIA CAPITAL INTERNATIONAL INC. is pleased to announce senior additions to its management team. Shoaib Sheikh, is joining as medical advisor, and Mr. Jason Batista is joining ...
TORONTO, Feb. 28, 2018-- BELGRAVIA CAPITAL INTERNATIONAL INC. is pleased to announce the execution of a binding letter of intent with R&D Pharma Corp. for the investment of one million Canadian dollars ...
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2017) - Belgravia Capital International (CSE: BLGV) (OTCQB: BLGVF) is the latest new listing on the Canadian Securities Exchange, trading under the symbol "BLGV", having previously traded as IC Potash on the Toronto Stock Exchange under the symbol "ICP". InvestmentPitch Media has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter ...